Cabot (CBT) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
2 Feb, 2026Executive summary
Q3 FY2024 adjusted EPS rose 35% year-over-year to $1.92, with diluted EPS at $1.94, driven by strong operational and segment performance.
Reinforcement Materials EBIT grew 3% to $136 million; Performance Chemicals EBIT surged 72% to $55 million, both supported by higher volumes and improved mix.
Net sales for Q3 2024 were $1,016 million, up 5% year-over-year, with net income attributable to Cabot at $109 million.
Operating cash flow reached $207 million, enabling $73 million in shareholder returns via dividends and share repurchases.
Achieved a Platinum EcoVadis sustainability rating for the fourth consecutive year and advanced sustainability initiatives.
Financial highlights
Adjusted EPS for Q3 FY24 was $1.92; diluted EPS was $1.94; net sales reached $1,016 million.
Operating cash flow was $207 million; discretionary free cash flow was $128 million; cash and equivalents stood at $197 million.
Capital expenditures for Q3 were $52 million; FY24 capex expected between $220 million and $240 million.
Net debt to EBITDA stood at 1.2x; total liquidity was $1.4 billion.
Q3 gross profit was $256 million, up from $223 million year-over-year.
Outlook and guidance
Raised full-year adjusted EPS guidance to $7.00–$7.10, up from $6.65–$6.85, reflecting strong segment performance.
Expects over 30% year-over-year adjusted EPS growth for FY2024 and to exceed $1 billion cumulative discretionary free cash flow from FY22–FY24.
Reinforcement Materials and Performance Chemicals segments are projected to maintain strong year-over-year growth, with sequential improvement in Reinforcement Materials and seasonal decline in Performance Chemicals in Q4.
Operating tax rate for FY2024 expected in the 27–28% range.
Latest events from Cabot
- Adjusted EPS down 13% to $1.53; Battery Materials up 39%, Reinforcement Materials EBIT down 22%.CBT
Q1 20264 Feb 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.CBT
Proxy Filing27 Jan 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with strong ESG focus.CBT
Proxy Filing27 Jan 2026 - 31% EPS growth, $265M returned to shareholders, and 2025 EPS guidance of $7.40–$7.80.CBT
Q4 202416 Jan 2026 - FY24 adjusted EPS guidance raised to $7.00–$7.10, driven by battery, E2C, and inkjet growth.CBT
Investor Day 202412 Jan 2026 - Adjusted EPS up 13% to $1.76; net income and cash flow drive strong shareholder returns.CBT
Q1 20259 Jan 2026 - Annual meeting to vote on directors, executive pay, new incentive plan, and auditor ratification.CBT
Proxy Filing1 Dec 2025 - Key votes include director elections, executive pay, incentive plan, and auditor ratification.CBT
Proxy Filing1 Dec 2025 - Q3 FY25 Adjusted EPS was $1.90, with mixed segment results and strong cash flow.CBT
Q3 202523 Nov 2025